Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical SM04554 in Male Subjects With Androgenetic Alopecia
NCT03742518Phase 3Completed
- Sponsor
- Biosplice Therapeutics
- Start
- Nov 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dalosirvat in androgenetic alopecia (AGA) (3 arms), sponsored by Biosplice Therapeutics. Primary endpoint: Absolute Non-vellus Hair Count in Target Area at 48 weeks. Started Nov 2018; status: completed.
02
Drugs
dalosirvat
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT03742518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742518.